ClinicalTrials.gg
TerminatedNCT06112080Updated Jul 5, 2024

Wearable Auscultation Device Validation in Children

An observational study in Asthma, Asthma in Children and Wheezing, sponsored by Strados Labs, Inc.. Terminated at 1 site in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Strados Labs, Inc. · Observational

How we know

Why this study was terminated
The Principal Investigator is departing from the study site.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Enrollment
250th of 330
36 · median 112
Started
2023
with 54 others
Observational
335 of 1,696
34 open now
Registered
1,555th of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 250th largest by enrollment of the 330 observational ones that give a count, is one of 55 that started in 2023, is one of 335 observational ones, and was the 1,555th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This observational clinical study is an evaluation of a diagnostic tool through comparison. Similar to a validation study, the output of the RESP device will be compared to physician auscultation, surrogated by having an attending pulmonologist listen to blinded recordings.

03

Conditions studied

  • Asthma
  • Asthma in Children
  • Wheezing
  • Pediatric Asthma
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

pediatric subjects who present to Lurie Children's Hospital with or without wheezing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any child aged 4-17 years of age
  • Admitted to Lurie Children's Hospital or the Emergency Department at Lurie
  • Normal breath sounds cohort: (16 patients ages 4-10, 16 patients ages 11-17)

    • Admitted for a non-respiratory complaint
    • Normal breath sounds on screening examination
  • Wheeze cohort: (53 patients ages 4-10, 53 patients ages 11-17)

    • Admitted for pathologic process that may lead to wheezing (e.g., asthma)
    • Presence of wheeze on screening examination

Exclusion criteria

Exclusion Criteria:

  • Children less than age 4, adults (age 18 and above)
  • Patients in the ambulatory setting
  • Unable to provide consent
  • Intubated patients
  • Unstable disease posing a threat to life
  • Adhesive allergy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (actual)
Patient registry
No

Groups and cohorts

  • Normal Breath Sound Cohort

    32 patients ages 4-10, 16 patients ages 11-17) * Admitted for a non-respiratory complaint * Normal breath sounds on screening examination

    Device: RESP™ Biosensor

  • Wheeze Cohort

    (106 patients ages 4-10, 53 patients ages 11-17) * Admitted for pathologic process that may lead to wheezing (e.g., asthma) * Presence of wheeze on screening examination

    Device: RESP™ Biosensor

Interventions

  • DeviceRESP™ Biosensor

    The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.

    Also known as: Remote Electronic Stethoscope Platform

06

What researchers measure

Primary outcomes

  1. Compare the output of the RESP Biosensor System to breath sound interpretation of an attending physician via collected recordings from stethoscope and completion of a comparison questionnaire

    PI will compare Strados RESP portal output with concurrent recordings collected via Littmann 300 Stethoscope. A questionnaire will be used to record and determine similarities and differences between RESP output and Littmann output, ultimately validating the intended use. Spectrographic data and audio recordings obtained via auscultation will be collected respectively by the RESP device and a separate recording stethoscope (Littman CORE Digital Stethoscope) simultaneously. Demographic and clinical data will be collected and stored in REDcap.

    Time frame: 12 months

Secondary outcomes

  1. Tolerability and usability assessed utilizing The System Usibility Scale to evaluate attitudes towards the use and tolerance of the device by patients and caregivers

    Assess the tolerability and usability of the Strados device by patients and caregivers utilizing the System Usability Scale will be used to evaluate subjects and caregivers attitudes towards the use and tolerance of the device. The System Usability Scale is a validated tool for evaluation of the usability and tolerability of a device or system by users. Then, subjects and caregivers will engage in a recorded interview using talk-aloud feedback. Recorded data will be transcribed and evaluated through quality analysis

    Time frame: 12 months

07

Study locations

1 site
  • Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jun 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 1, 2023
StartActual
Aug 7, 2023
Primary completionActual
Jun 24, 2024
CompletionActual
Jun 24, 2024
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06112080
Lead sponsor
Strados Labs, Inc.
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Aug 7, 2023
Primary completion
Jun 24, 2024
Completion
Jun 24, 2024
Last update
Jul 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion